求英文文献两篇，谢谢！

zhusealin

http://www.ncbi.nlm.nih.gov/pubmed/23271432
# I+ F2 e" r5 U杂志：Cell Mol Biol Lett. 2013 Mar;18(1):75-88. doi: 10.2478/s11658-012-0040-5. Epub 2012 Dec 27.& W; G3 q! L; H  a
题目：Differentiation of mesenchymal stem cells derived from human bone marrow and subcutaneous adipose tissue into pancreatic islet-like clusters in vitro.  {/ z) K; s4 C: f7 Y; {
/ ?8 N6 b7 d$ I- s
http://www.nature.com/nrendo/jou ... rendo.2014.172.html" h) r# I, C, [5 L- ?) r) h
杂志：NATURE REVIEWS ENDOCRINOLOGY" K; h9 D  d8 ?# M0 x
题目：MSC transplant prevents β-cell dysfunction

chichao0000

Differentiation of mesenchymal stem cells derived from human bone marrow and subcutaneous adipose tissue into pancreatic islet-like clusters in vitro

chichao0000

第二篇又无法上传了，不过没关系，那篇文章就直接粘在下面了：# ~& S' y8 p- Z- H" W
Current treatments for type 1 diabetes mellitus (T1DM) only temporarily halt the progressive loss of pancreatic β cells that characterizes the disease. Now, a new study shows that autologous mesenchymal stromal cell (MSC) transplantation can preserve β-cell function for up to 1 year in patients with new-onset T1DM.
" R+ h; i: b; I, s% c# v0 @& O% Q! @% L- `2 w
Previous studies in animal models of T1DM have shown that MSCs (nonhaematopoietic cells that mediate tissue regeneration and repair) can home to and promote the repair of damaged pancreatic islets. These findings, together with the success of intervention studies with MSCs in other diseases, led the researchers to investigate the safety and efficacy of this treatment in patients with T1DM.6 x2 y0 Q9 \3 L/ R4 B3 A

  @+ Z9 }8 z7 e4 ~' kThis open-label single-centre pilot study included 20 newly diagnosed patients with T1DM who were randomly assigned to either MSC treatment or insulin-only treatment (control group). MSCs were isolated from the bone marrow of the participants of the MSC treatment group and expanded ex vivo for 1–2 passages before being returned to the same patients in a single intravenous infusion. Residual β-cell function (insulin secretion) was assessed by the C-peptide response to a mixed-meal tolerance test.
9 Z3 L: L* E. w4 G# K& j& T7 H, ~9 E$ o/ J% N7 g$ X
Patients treated with MSCs had preserved or even increased C-peptide responses after 1 year, in contrast to control patients who showed the expected deterioration in insulin production. Reassuringly, no adverse effects were observed in the MSC treatment group. “Autologous MSC treatment of patients with recent-onset T1DM constitutes a safe and promising strategy to prevent disease progression and preserve β-cell function,” concludes lead investigator Per-Ola Carlsson. Recruitment for a follow-on double-blind randomized phase II study is currently underway.
7 U2 i0 ?' a( D4 a3 w
( v- D. Y; n, uReferences( ?: U% d# f( `2 w- Y6 h# e
Carlsson, P.-O. et al. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes doi:10.2337/db14–0656